Stock Price Quote

CAPLIN POINT LABORATORIES LTD.

NSE : CAPLIPOINTBSE : 524742ISIN CODE : INE475E01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE1315.051 (+0.08 %)
PREV CLOSE ( ) 1314.05
OPEN PRICE ( ) 1305.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4261
TODAY'S LOW / HIGH ( )1293.45 1322.35
52 WK LOW / HIGH ( )647.1 1617.8
NSE1311.70-4.8 (-0.36 %)
PREV CLOSE( ) 1316.50
OPEN PRICE ( ) 1318.00
BID PRICE (QTY) 1311.70 (7)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 72593
TODAY'S LOW / HIGH( ) 1290.00 1318.00
52 WK LOW / HIGH ( )646.8 1619.05
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1990
Management Info
C C Paarthipan - Chairman Sridhar Ganesan - Managing Director
Registered Office

Address 3rd Floor, “ Ashvich Towers”,No.3, Developed Plots Industrial Estate,Perungudi,
Chennai,
Tamil Nadu-600096

Phone 044-24968000 / 8012772888 / 71148000

Email info@caplinpoint.net

Website www.caplinpoint.net

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai
Listing : BSE, NSE, Chennai

NEWS

16Apr Caplin Point Laboratories’ arm gets fi
Caplin Point Laboratories’ subsidiary company -- Caplin Steriles (Caplin..
16Apr Caplin Point Laboratories informs abou
Caplin Point Laboratories has informed that it enclosed press release re..
28Mar Caplin Point Laboratories’ arm gets US
Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been grante..
28Mar Caplin Point Laboratories gains as its
Caplin Point Laboratories is currently trading at Rs. 1283.80, up by 23...
28Mar Caplin Point Laboratories informs abou
Caplin Point Laboratories has attached a Press Release regarding grant o..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit554.52342.6
Gross Profit 744.3 2931.5
Operating Profit 812.23189.2
Net Sales 1328.35286.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

PROMOTERS 70.62%
NON-INSTITUTION 24.95%
MUTUAL FUNDS/UTI 1.06%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Caplin Point Laboratories Ltd.

Caplin Point Laboratories Ltd. was incorporated in the year 1990. Its today's share price is 1315.05. Its current market capitalisation stands at Rs 9986.72 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5286.1 Cr and Total Income of Rs.6281.5 Cr. The company's management includes S Deenadhayalan, R Nagendran, CK Gariyali, D Sathyanarayanan, Sridhar Ganesan, C C Paarthipan, G Venkatram.

It is listed on the BSE with a BSE Code of 524742 , NSE with an NSE Symbol of CAPLIPOINT and ISIN of INE475E01026. It's Registered office is at 3rd Floor, “ Ashvich Towers”,No.3, Developed Plots Industrial Estate,PerungudiChennai-600096, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are CNGSN & Associates, CNGSN & Associates LLP, M Raghunath & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.